195 related articles for article (PubMed ID: 14529657)
1. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
2. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
Caudell JJ; Deavers MT; Slomovitz BM; Lu KH; Broaddus RR; Gershenson DM; Ramondetta LM
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):167-70. PubMed ID: 15894930
[TBL] [Abstract][Full Text] [Related]
4. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary.
Klein WM; Kurman RJ
Int J Gynecol Pathol; 2003 Apr; 22(2):181-4. PubMed ID: 12649674
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
6. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT.
Raspollini MR; Pinzani P; Simi L; Amunni G; Villanucci A; Paglierani M; Taddei GL
Gynecol Oncol; 2005 Aug; 98(2):334-5. PubMed ID: 16039311
[No Abstract] [Full Text] [Related]
7. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
[TBL] [Abstract][Full Text] [Related]
8. KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature.
Zafrakas M; Theodoridis TD; Zepiridis L; Venizelos ID; Agorastos T; Bontis J
Eur J Gynaecol Oncol; 2008; 29(3):264-6. PubMed ID: 18592792
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
11. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
12. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region.
Nakayama M; Mitsuhashi T; Shimizu Y; Ban S; Ogawa F; Ishihara O; Shimizu M
Int J Gynecol Pathol; 2006 Jan; 25(1):70-6. PubMed ID: 16306788
[TBL] [Abstract][Full Text] [Related]
14. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors.
Kinoshita K; Isozaki K; Hirota S; Nishida T; Chen H; Nakahara M; Nagasawa Y; Ohashi A; Shinomura Y; Kitamura Y; Matsuzawa Y
J Gastroenterol Hepatol; 2003 Feb; 18(2):147-51. PubMed ID: 12542597
[TBL] [Abstract][Full Text] [Related]
15. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
16. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
17. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
Kim DJ; Lee MH; Park TI; Bae HI
J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
[TBL] [Abstract][Full Text] [Related]
18. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas.
Jeffers MD; Richmond JA; Macaulay EM
Mod Pathol; 1995 Sep; 8(7):701-4. PubMed ID: 8539225
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target.
Komdeur R; Hoekstra HJ; Molenaar WM; Van Den Berg E; Zwart N; Pras E; Plaza-Menacho I; Hofstra RM; Van Der Graaf WT
Clin Cancer Res; 2003 Aug; 9(8):2926-32. PubMed ID: 12912938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
